Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2004
04/20/2004US6723372 Spraying grains which consist of a prostane derivative and a cyclodextrin vehicle, forming together a prostane-cyclodextrine-clathrate, with an aqueous polymer dispersion of ethyl cellulose and/or poly(methyl)acrylic acid ester
04/20/2004US6723358 Encapsulation of components into edible products
04/20/2004US6723353 Preserved cyclodextrin-containing compositions
04/20/2004US6723350 Powder of one or more antimicrobial metals formed with atomic disorder; coating becomes antimicrobial and anti-inflammatory when wet.
04/20/2004US6723348 Orodispersible tablets containing fexofenadine
04/20/2004US6723345 Topical drug preparations
04/20/2004US6723344 Useful as implantable devices and wound dressings as the matrix of the invention is designed to be used in conjunction with such devices to provide protracted and controlled release of growth factor, to promote wound healing
04/20/2004US6723343 Pharmaceutical tramadol salts
04/20/2004US6723342 Edible coating composition
04/20/2004US6723340 Optimal polymer mixtures for gastric retentive tablets
04/20/2004US6723339 Hard gelatine capsule
04/20/2004US6723337 Non-aqueous acrylic polymer, superior adhesion and durability instead of water-soluble polymer significantly decreases thickness of patch; non-ionic surfactant and terpene are used as absorption enhancers; dissolution assistant is used
04/20/2004US6723326 Topical compositions containing probiotic Bacillus bacteria, spores, and extracellular products and uses thereof
04/20/2004US6723320 Using monoclonal antibodies; polymerase chain reactions
04/20/2004US6723318 Targeting of biomolecules
04/20/2004US6723229 From mineral oil distillates; hydrotreatment; hydrogenation/ hydrodesulfurization; producing a product stream which is low in aromatics and which has substantially ?nil? sulfur; and selective hydrogenation
04/20/2004CA2247405C Slow-release pharmaceutical formulations containing mizolastin
04/20/2004CA2192725C Camptothecin derivatives
04/20/2004CA2125408C Drug formulations for parenteral use
04/20/2004CA2102778C Novel compositions based on taxane class derivatives
04/20/2004CA2054822C Formulations and their use in the treatment of neurological diseases
04/20/2004CA2044593C Method of in vivo delivery of functioning foreign genes
04/17/2004CA2444781A1 Topical gel matrix
04/15/2004WO2004031379A1 Proteins having polysaccharidase activity
04/15/2004WO2004031221A1 Tumor targeting agents and uses thereof
04/15/2004WO2004031220A1 Tumor targeting agents and uses thereof
04/15/2004WO2004031214A1 Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same, and processes for producing these
04/15/2004WO2004030701A1 Conjugated hydroxyalkyl starch allergen compounds
04/15/2004WO2004030691A1 Sustained release preparation containing nk4
04/15/2004WO2004030687A1 Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
04/15/2004WO2004030667A1 Nasal drop composition
04/15/2004WO2004030665A1 Transparent gel composition, for the administration of diclofenac sodium through the skin
04/15/2004WO2004030661A2 Therapeutic compositions comprising a boron-containing compound
04/15/2004WO2004030650A2 Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
04/15/2004WO2004030623A2 Nitroxide radioprotector formulations and methods of use
04/15/2004WO2004030617A2 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
04/15/2004WO2004030610A2 Compositions and methods for the intracellular delivery of antibodies
04/15/2004WO2004022630A3 Water-soluble polymer alkanals
04/15/2004WO2004019991A3 Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
04/15/2004WO2004017962A3 Tropical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region
04/15/2004WO2004009774A3 Protein conjugates with a water-soluble biocompatible, biogradable polymer
04/15/2004WO2004004689A8 Compositions and methods for amelioration of human female sexual dysfunction
04/15/2004WO2004002398A3 Spherical pellet containing a water-soluble active ingredient
04/15/2004WO2003088956A8 Method for treating ileus with an alpha -ketoalkanoic acid or - ester or - amide
04/15/2004WO2003086471A3 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin
04/15/2004WO2003077888A3 Compressed tablets comprising microcapsules with modified release
04/15/2004WO2003066064A3 Methods of resistant bacterial disease treatment using metal-complexed tetracycline antibiotics
04/15/2004WO2003054543A3 Probe for mass spectrometry
04/15/2004WO2003028527A8 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
04/15/2004WO2003022217A9 Treatment of excessive radiation (e.g. sunburn) exposure
04/15/2004WO2002055721A3 Modular transfection systems based on nucleoprotein filaments
04/15/2004WO2002016553B1 Regulator gene and system useful for the diagnosis and therapy of osteoporosis
04/15/2004WO2002009690A8 Pharmaceutical composition comprising a photochemotherapeutic agent and a mucoadhesive agent
04/15/2004US20040073964 Using washing media containing polysaccharide containing arabinose, galactose and fatty acid units; activation ; storage; prevent cellular damage
04/15/2004US20040073296 Inhibition of restenosis using a DNA-coated stent
04/15/2004US20040072986 Ring opening polymerization of lactide, glycolide in presence of dextran sulfate in an extruder; sustained release; drug delivery
04/15/2004US20040072961 Multiblock biodegradable hydrogels for drug delivery and tissue treatment
04/15/2004US20040072911 Mixture of antiseptic, bactericide and lubricant
04/15/2004US20040072909 Veterinary compositions for the treatment of parasitic diseases
04/15/2004US20040072904 Powder mixture of aminobutyric acid and solid polyol; therapy for brain disorders; central nervous system disorders; analgesics; headaches
04/15/2004US20040072810 Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
04/15/2004US20040072799 Drug delivery; mixture of cyclodextrin and amphiphilic copolymer
04/15/2004US20040072798 Compositions comprising cyclodextrins and no-releasing drugs
04/15/2004US20040072797 In liquid siolvent; parenterally administering; aldosterone receptors blockers; congestive heart failure, hypotensive agents, liver disorders
04/15/2004US20040072795 Complex of Dna and lipid with detectable label; accuracy positioning; anticancer agents, antiinflammatory agents
04/15/2004US20040072793 Amide derivatives; scaffold for tissue regeneration; drug delivery biodegradable; tissue adhesive
04/15/2004US20040072792 Local anesthetic and agent for maintaining anesthetic action; acidic mucopolysaccharide or a cellulose derivative; does not contain a catecholamine; for oral surgery or dental treatment; sodium chondroitin sulfate; hydroxypropylmethylcellulose
04/15/2004US20040072785 Ischemia; polynucleotide for transfection; polynucleotide is inserted into an artery or a vein; prior to injection the volume of the muscle tissue is increased such that the genetic material is delivered to the parenchymal cell
04/15/2004US20040072784 Micelles formed from amphiphilic polymers associate or dissociate reversibly upon ph changes; oral or parenteral delivery of hydrophobic or cationic pharmaceutical; copolymer of polyethylene oxide and polyacrylic acid-butyl acrylate
04/15/2004US20040072779 A mammalian target gene and an exogenous oligoribonucleotide having a double stranded RNA; complementary region I is less than 49 nucleotides in length; cancer, viral diseases, neurodegenerative diseases
04/15/2004US20040072766 Bioassay for screening an inhibitor or activator of phosphatidylinositol 3-kinase, finding immunostimulants, or immunosuppressants
04/15/2004US20040072759 Polypeptides
04/15/2004US20040072755 A fusion proteins, a binding proteins as anticarcinogenic agents for treating cancer, antiinflammatory agents, treating atherosclerosis and ischemia/ reperfusion
04/15/2004US20040072743 Pharmaceutical composition of modified pna molecules
04/15/2004US20040072735 Administering suberoylanilide hydroxamic acid (SAHA) to inhibit histone deacetylase (HDAC) to a patient for cancer cell growth arrest and/or apoptosis of neoplastic cells
04/15/2004US20040072729 Administering PEG-hemoglobin (polyethylene glycol-conjugated hemoglobin) solution with specific ability to deliver oxygen to cells of a mammal under ischemia or hypoxia
04/15/2004US20040072726 Decoy is an NF- kappa B decoy, an ets decoy, or a chimera decoy of NF- kappa B and ets. The disease is cerebral aneurysm, cancer, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic etc.
04/15/2004US20040072340 Use of peptide vectors to improve the immune response to antigens
04/15/2004US20040072291 Comprises genetically engineered nerve growth factor for diagnosis and treatment of nervous system and neurodegenerative disease
04/15/2004US20040072222 A conformational model of linear epitope sequence from guinea pig MBP72-85 and human MBP87-99
04/15/2004US20040072219 Genetically engineered obesity protein with reduced immune response for treatment of diabetes, high blood pressure and cholesterol metabolism disorders
04/15/2004US20040071784 Composite material and process for increasing bioavailability and activity of a beneficial agent
04/15/2004US20040071782 Ionophore antibiotic formulations
04/15/2004US20040071779 Gelled laxative compositions
04/15/2004US20040071778 Gel administered as drops or ointment with free-flowing vehicle and benzyllauryldimethylammonium chloride preservative
04/15/2004US20040071777 In hydrophilic cellulose ether, polyvinyl pyrrolidone, or polyethylene glycol; amorphous
04/15/2004US20040071775 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
04/15/2004US20040071774 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
04/15/2004US20040071771 Fenofibrate-containing composition
04/15/2004US20040071769 Buffer, surfactant, chelate compound, nonionic preservative microbiocide; sensitivity; wound healing agents; topical, drug delivery
04/15/2004US20040071767 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
04/15/2004US20040071765 Electrconductive layer containing basic and/or acidic water swelling methacrylate copolymer; transdermal drug delivery
04/15/2004US20040071764 Transdermal therapeutic system for administering non-steroidal antiphlogistic agents containing carboxyl groups, and a method for the production of the same
04/15/2004US20040071763 Composition for use in electroporation
04/15/2004US20040071755 Water soluble sheet composition
04/15/2004US20040071753 Enhancement of development of oviparous species by in ovo feeding of enteric modulators
04/15/2004US20040071748 Stable hydroalcoholic compositions
04/15/2004US20040071736 Topicalyl administering light chain fragment of clostridial neurotoxin including active proteolytic enzyme domain; chronic obstructive pulmonary disease (COPD) treatment; antiasthmatics and antisecretory agents
04/15/2004US20040071735 Bone and muscular disorder treatment
04/15/2004US20040071734 Novel vaccine